Zastosowanie pozytonowej tomografii emisyjnej w medycynie i medycynie weterynaryjnej

• Autorzy: Lojszczyk A. , Debiak P. , Jarzabek-Bielecka G. , Kedzia W. , Mizgier M.

Warianty tytułu

EN

Use of positron emission tomography in medicine and veterinary medicine

• Języki publikacji: PL

Abstrakty

EN

Positron emission tomography (PET) is an imaging technique using positron (anti-electron) radiopharmaceuticals, in which radiation generated during the annihilation of positrons is recorded. This method is used in oncology, neurology and cardiology. PET is of particular importance to oncology, in both scientific and clinical research, especially in the identification and staging of metastatic disease, as well as in therapy planning and control. The use of PET has contributed to the advancement of research into many neurological problems. Data in the literature indicate that PET is widely used in veterinary medicine. PET allows for detailed evaluation of many oncologic and fungal diseases. In neurology, it has been used in necrotizing meningoencephalitis and epilepsy. There have been a number of experimental studies in cardiology, as well, in patients after radiation therapy.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2020
• Tom: 76
• Numer: 04
• Opis fizyczny: s.200-205,bibliogr.

Twórcy

autor

Lojszczyk A.

• Pracownia Radiologii i Ultrasonografii, Katedra i Klinika Chirurgii Zwierząt, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, ul. Głęboka 30, 20-612 Lublin

autor

Debiak P.

• Pracownia Radiologii i Ultrasonografii, Katedra i Klinika Chirurgii Zwierząt, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, ul. Głęboka 30, 20-612 Lublin

autor

Jarzabek-Bielecka G.

• Klinika Ginekologii, Katedra Perinatologii i Ginekologii,Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, ul. Polna 33, 60-535 Poznań

autor

Kedzia W.

• Klinika Ginekologii, Katedra Perinatologii i Ginekologii,Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, ul. Polna 33, 60-535 Poznań

autor

Mizgier M.

• Zakład Dietetyki - Zamiejscowy Wydział Kultury Fizycznej w Gorzowie Wielkopolskim, Akademia Wychowania Fizycznego im. Eugeniusza Piaseckiego w Poznaniu, ul. Estkowskiego 13, 66-400 Gorzów Wielkopolski

Bibliografia

• 1. Alberini J. L., Lerebours F., Wartski M., Fourme E., Le Stanc E., Gontier E., Madar O., Cherel P., Pecking A. P.: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer 2009, 115, 5038-5047.
• 2. Alstrup A. K., Smith D. F.: Anasthesia for positron emission tomography scanning of animal brains. Laboratory Animals 2013, 47, 12-18.
• 3. Aukema T. S., Rutgers E. J., Vogel W. V., Teertstra H. J., Oldenburg H. S., Vrancken Peeters M. T., Wesseling J., Russell N. S., Valdes Olmos R. A.: The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques. Eur. J. Surg. Oncol. 2010, 36, 387-392.
• 4. Baleeger E. A., Hollinger Ch., Kunst Ch. M.: Imaging diagnosis – multi centric lymphoma of granular lymphocytes imaged with FGD PET/CT in a dog. Vet. Radiol. Ultrasound 2013, 54, 75-80.
• 5. Boland G. W., Blake M. A., Holalkere N. S., Hahn P. F.: PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. Am. J. Roentgol. 2009, 192, 956-962.
• 6. Champion L., Brain E., Giraudet A. L., Le Stance E., Wartski M., Edeline V., Madar O., Bellet D., Pecking A., Alberini J. L.: Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer 2011, 117, 1621-1629.
• 7. Cheng X., Li Y., Liu B., Xu Z., Bao L., Wang J.: 18-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Acta Radiol. 2012, 53, 615-627.
• 8. Choi H. J., Ju W., Myung S. K., Kim Y.: Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci. 2010, 101, 1471-1479.
• 9. Ding X. P., Feng L., Ma L.: Diagnosis of recurrent uterine cervical cancer: PET versus PET/CT: a systematic review and meta-analysis. Arch. Gynecol. Obstet. 2014, 290, 741-747.
• 10. Dirisamer A., Halpern B. S., Flőry D., Wolf F., Beheshti M., Mayerhoefer M. E., Langsteger W.: Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur. J. Radiol. 2010, 73, 294-299.
• 11. Eom K. D., Lim Ch. Y., Gu S. H., Kang B. T., King Y. B., Jang D. P., Woo E. J., Kim D., Cho Z. H., Park H. M.: Positron Emission tomography features of canine necrotizing meningoencephalitis. Vet. Radiol. Ultrasound 2008, 49, 595-599.
• 12. Frank I., Mann K., Duerr F.: Fluorine – 18-fluoro-2-deoxy-D-glucose PET-CT aids in detection of soft tissue injuries for dogs with thoracic or pelvic limb lameness. Vet. Radiol. Ultrasound 2019, 60, 575-585.
• 13. Fularz M., Adamiak P., Czepczyński R., Jarząbek-Bielecka G., Kędzia W., Ruchała M.: Positron emission tomography (PET) in malignant ovarian tumors. Ginekol. Pol. 2013, 84, 720-725.
• 14. Garami Z., Hascsi Z., Varga J., Dinya T., Tanyi M., Garai I., Damjanovich L., Galuska L.: The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan. Eur. J. Surg. Oncol. 2012, 38, 31-37.
• 15. Ghooshkhanei H., Treglia G., Sabouri G., Davoodi R., Sadeghi R.: Risk stratification and prognosis determination using (18)F-FDG PET imaging in endometrial cancer patients: a systematic review and meta-analysis. Gynecol. Oncol. 2014, 132, 669-676.
• 16. Griffin L. R., Thamm D. H., Selmic L. E., Ehrhart L. E., Randall E.: Pilot study utlizing Fluorine – 18 fluorodeoxyglucose-positron emission tomography/ computed tomography for glycolytic phenotypic of canine mast cell tumors. Vet. Radiol. Ultrasound 2018, 59, 461-468.
• 17. Grobman M., Cohn L., Knapp S., Bryan J., Reinero C.: 18 F-FGD PET/CT as adjunctive diagnostic modalities in canine fever of unknot origin. Vet. Radiol. Ultrasound 2018, 59, 107-115.
• 18. Groheux D., Hindie E., Delord M., Giacchetti S., Hamy A. S., Bazelaire C. de, Roquancourt A. de, Vercellino L., Toubert M. E., Merlet P., Espié M.: Prognostic impact of 18 FDG-PET-CT findings in clinical stage III and IIB breast cancer. J. Natl. Cancer Inst. 2012, 104, 1879-1887.
• 19. Hansen A. E., McEvoy F., Engenholm S. A., Law I., Kristensen A. T.: FGD PET/CT imaging in canine cancer patients. Vet. Radiol. Ultrasound 2011, 52, 201-206.
• 20. Hansen H. V., Loft A., Berthelsen A. K., Christensen I. J., Høgdall C., Engelholm S. A.: Survival outcomes in patients with cervical cancer after inclusion of PET/ CT in staging procedures. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 1833-1839.
• 21. Heusner T. A., Kuemmel S., Hahn S., Koeninger A., Otterbach F., Hamami M. E., Kimmig K. R., Forsting M., Bockisch A., Antoch G., Stahl A.: Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 1543-1550.
• 22. Hong S., Junhong L., Wang S.: 18 FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. Surg. Oncol. 2013, 22, 139-143.
• 23. Jodłowska E., Czepczyński R., Czarnywojtek A., Rewers A., Jarząbek G., Kędzia W., Ruchała M.: The application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part II. Diagnosis after treatment initiation, future perspectives. Współcz. Onkol. 2016, 20, 205-209.
• 24. Jodłowska E., Czepczyński R., Wyszomirska A., Jarząbek-Bielecka G., Kędzia W., Ruchała M.: Application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Pt. Diagnosis of breast cancer prior to treatment. Współcz. Onkol. 2016a, 20, 8-12.
• 25. Jokinen T. S., Haaparanta-Solin M., Vitmaa R., Gronroos T. J., Johansson J., Bergamasco L., Snellman M., Metsahonkala L.: FGD-PET in helathy and epileptic lag otto romagnolo dogs and changes in brain glucose uptake with age. Vet. Radiol. Ultrasound 2014, 55, 331-341.
• 26. Kadkhodayan S., Shahriari S., Treglia G., Yousefi Z., Sadeghi R.: Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol. Oncol. 2013, 128,397-404.
• 27. Kang S., Kim S. K., Chung D. C., Seo S. S., Kim J. Y., Nam B. H., Park S. Y.: Diagnostic value of (18)F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a metaanalysis. J. Nucl. Med. 2010, 51, 360-367.
• 28. Katayama T., Kubota K., Machida Y., Toriihara A., Shibuya H.: Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers. Ann. Nucl. Med. 2012, 26, 426-435.
• 29. Kim J., Kwon S. Y., Cena R., Park S., Oh J., Oui H., Cho K. O., Min J., Choi J.: CT and PET-CT of a dog with multiple pulmonary adenocarcinoma. J. Vet. Med. Sci. 2014, 76, 615-620.
• 30. Kobyłecka M., Mazutek T., Królicki L.: Ocena żywotności mięśnia sercowego w PET. Kardiologia po dyplomie 2009, 8, 51-58.
• 31. Królicki L., Kunikowska J., Kobyłecka M., Mączewska J., Fronczewska K.: Znaczenie pozytnowej tomografii emisyjnej (PET) w diagnostyce schorzeń onkologicznych. Postępy Nauk Medycznych 2011, 2, 104-108.
• 32. Krutchen M. van, Glaudemans A. W., de Vries E. F., Beets-Tan R. G., Schrӧder C. P., Dierckx R. A., de Vries E. G., Hospers G. A.: PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J. Nucl. Med. 2012, 53, 182-190.
• 33. Kuwert T., Bartenstein P., Gruwald F. i wsp.: Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinar consensus conference. Nervenartz 1998, 69, 1045-1060.
• 34. Lawrence J., Vanderhoek M., Barbee D., Jeraj R., Tumas D. B.: Use of 3’deoxy’[18F] fluorothymsidine PET/CT for evaluating response for cytotoxic chemotherapy in dogs with non-hodgkin’s lymphoma. Vet. Radiol. Ultrasound 2009, 50, 660-668.
• 35. LeBlanc A. K., Jakoby B. W., Townsend D. W., Daniel G. B.: 18 FGD PET imaging in canine lymphoma and cuteness mast cell tumor. Vet. Radiol. Ultrasound 2009, 50, 215-223.
• 36. LeBlanc A. K., Jakoby B. W., Townsend D. W., Daniel G. B.: Thoracic and abdominal organ uptake of 2-deoxy-2-{18F} fluoro;D-glucose (18FGD) with positron emission tomography in normal dogs. Vet. Radiol. Ultrasound 2008, 49, 182-188.
• 37. LeBlanc A. K., Miller A. N., Galyon G. D., Moyers T. D., Long M. J., Stuckey A. C., Wall J. S., Morand F.: Preliminary evaluation of serial 18FGD-PET/CT to access response to Toceranib phosphate therapy in canine cancer. Vet. Radiol. Ultrasound 2012, 53, 348-357
• 38. LeBlanc A. K., Morandi F.: Invited review-off-site pet imaging programs: challenges and opportunities. Vet. Radiol. Ultrasound 2014, 55, 109-112.
• 39. LeBlanc A. L., Wall J. S., Morandi F., Kennel S. J., Stuckey A., Jakoby B., Townsend D. W., Daniel G. B.: Normal thoracic and abdominal distribution of 2-deoxy-2-[18F] fluoro-D-glucose (18 FGD) in adult cats. Vet. Radiol. Ultrasound 2009, 50, 436-441.
• 40. Martinez N. E., Kraft S. L., Gibbons D. S., Arceneaux B. L., Stewart J. A., Mama K. R., Johnson T. E.: Occupational per-patient radiation dose from a conservative protocol for veterinary 18F-fluorodeoxyglucose positron emission tomography. Vet. Radiol. Ultrasound 2012, 53, 591-597.
• 41. Mghanga F. P., Lan X., Bakari K. H., Li C., Zhang Y.: Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis. Clin. Breast. Cancer 2013, 13, 271-279.
• 42. Ogawa T., Inugami A., Hatazawa J., Kanno I., Murakami M., Yasui N., Mineura K., Uemura K.: Clinical poistron emission tomography for brain tumors: comparison of fludeoxyglucose F and L-methyl-11C-methionine. Am. J. Neurodial. 1996, 17, 345-353.
• 43. Randall E.: PET – Computed tomography in veterinary medicine. Vet. Clin. Small Anim. 2016, 46, 515-533.
• 44. Randall E., Loeber S., Kraft S.: Physiologic variants, beningn processes, and artifacts from 106 canine and feline FDG-PET/computed tomography scans. Vet. Radiol. Ultrasound 2014, 55, 213-226.
• 45. Randall E. K., Kraft S. L., Yoshikawa H., Larue S. M.: Evaluation of 18F-FDG PET/CT as a diagnostic imaging and staging tool for feline oral suamus cell carcinoma. Vet. Comp. Oncol. 2013, 14, 28-38.
• 46. Riegger C., Herrmann J., Nagarajah J., Hecktor J., Kuemmel S., Otterbach F., Hahn S., Bockisch A., Lauenstein T., Antoch G., Heusner T. A.: Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 852-863.
• 47. Rowe J. A., Morandi F., Wall J. S., Akula M., Kennel S. J., Osborne D., Martin E. B., Galyon G. D., Long M. J., Stuckey A. C., LeBlanc A.: Whole body biodistribution of 3’-deoxy-3’-[18F] fluorothymide (18FLT) in healthy adult cats. Vet. Radiol. Ultrasound 2013, 54, 299-306.
• 48. Salem A., Salem A. F., Al-Ibraheem A., Lataifeh I., Almousa A., Jaradat I.: Evidence for the use PET for radiation therapy planning in patients with cervical cancer: a systematic review. Hematol. Oncol. Stem. Cell. Ther. 2011, 4, 173-181.
• 49. Salmon E., Bernard C., Hustinx R.: Pitafalls and limitations of PET/CT in brain imaging. Seminars in Nuclear Medicine 2015, 45, 541-551.
• 50. Song J., Yan R., Wu Z., Li J., Yan M., Hao X., Liu J., Li S.: 13N – Ammonia PET/CT detection of myocardial perfusion abnormalities in beagle dogs after local heart irradiation. J. Nucl. Med. 2017, 58, 605-610.
• 51. Song S. H., PArk N. W., Eom K. D.: Positron emission tomography/computed tomography imaging features of renal cell carcinoma and pulmonary metastases in a dog. Can. Vet. J. 2014, 55, 466-470.
• 52. Souza M. J., Wall J. S., Stuckey A., Daniel G. B.: Static and dynamic 18FGDPET in normal Hispaniola amazon parrots (amazona ventralis). Vet. Radiol. Ultrasound 2011, 52, 340-344.
• 53. Spriet M., Espinoza P., Kyme A. Z., Stepanov P., Zavarzin V., Schaefer S., Katzman S. A., Galuppo L. D., Beylin D.: Postron emission tomography of the equine distal limb: exploratory study. Vet. Radiol. Ultrasound 2016, 57, 630-638.
• 54. Valdes-Martinez A., Kraft S., Brundage S. M. et al.: Assessment of blood pool, soft tissue and skeletal uptake of sodium fluoride F18 with. Positron emission tomography-computed tomography in four clinically normal dogs. Am. J. Vet. Res. 2012, 73, 1589-1595.
• 55. Vitmaa R., Haaparatnta-Solin M., Senllman M., Cizinauskas S., Orro T., Kuusela E., Johansson J., Viljanen T., Jokinen T. S., Bergamasco L., Metsahonkala L.: Cerebral glucose utilization measured with high resolution positron emission tomography in epileptic Finnish spitz dogs and healthy dogs. Vet. Radiol. Ultrasound 2014, 55, 453-461.
• 56. Wang Y., Zhang C., Liu J., Huang G.: Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res. Treat. 2012, 131, 357-369.
• 57. Windorbska W., Lewandowska A.: Pozytonowa tomografia emisyjna – nowe narzędzie diagnostyczne w onkologii. Journal of oncology 2004, 54, 50-53.
• 58. Xiao Y., Wei J., Zhang Y., Xiong W.: Positron emission tomography alone, positron emission tomography-computed tomography and computed tomography in diagnosing recurrent cervical carcinoma: a systematic review and meta-analysis. Arch. Med. Sci. 2014, 10, 222-231.
• 59. Yoshikawa H., Randall E. K., Kraft S. L., LaRue S. M.: Comparison between 2-18F-fluoro-2-deoxy-D-Glucose positron emission tomography and contrastenhanced connoted tomography for measuring gross tumor volume in cats with oral squamous cell carcinoma. Vet. Radiol. Ultrasound 2013, 54, 307-313.

Identyfikatory

DOI

10.21521/mw.6388